{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:58Z","timestamp":1787020858372,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 54-year-old Caucasian male was referred to the Haematology Unit with an enlarged inguinal lymph node which was diagnostic of a blastic plasmacytoid dendritic cell neoplasm. The staging revealed disseminated disease (skin, visceral, lymph nodes, and bone marrow).\u00a0He received chemotherapy with an acute myeloid leukaemia-like regime. Afterwards, he underwent allogeneic haematopoietic stem cell transplantation, though it was not successful, showing a relapse 14 months later with hepatic and central nervous system dissemination. Intrathecal chemotherapy was administered, and venetoclax (anti-bcl2 agent) was started in an off-label indication based on most recent literature. The disease halted its course for 3 months. In the end, the patient\u2019s disease progressed and so he succumbed due to infectious complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Venetoclax monotherapy seems not enough to control the disease progression under CNS involvement and other treatments should be investigated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-021-02939-7","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T19:06:07Z","timestamp":1624647967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Venetoclax in relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a\u00a0case report and review of the literature"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2942-1362","authenticated-orcid":false,"given":"Nil","family":"Albiol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mozos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pratcorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"1","key":"2939_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11864-019-0605-x","volume":"20","author":"D Kerr","year":"2019","unstructured":"Kerr D, Zhang L, Sokol L. Blastic plasmacytoid dendritic cell neoplasm. Curr Treat Options Oncol. 2019;20(1):9.","journal-title":"Curr Treat Options Oncol"},{"key":"2939_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood.V126.23.23.23","volume":"126","author":"E Poret","year":"2015","unstructured":"Poret E, Vidal C, Desbrosses Y, Angelot Delettre F, Pagadoy M, Pugin A, et al. How to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) Patients\u202f: results on 86 patients of the French BPDCN Network. Blood. 2015;126:23.","journal-title":"Blood."},{"issue":"5","key":"2939_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017;179(5):781\u20139.","journal-title":"Br J Haematol"},{"issue":"8","key":"2939_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2019001144","volume":"134","author":"J Taylor","year":"2019","unstructured":"Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pre-targeted therapy benchmark. Blood. 2019;134(8):678\u201387.","journal-title":"Blood."},{"issue":"3","key":"2939_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401\u20137.","journal-title":"Am J Hematol"},{"key":"2939_CR6","unstructured":"Steven H. Swerdlow, Elias Campo, Nancy Lee Harris. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Steven H. Swerdlow, Elias Campo, Nancy Lee Harris, Elaine S. Jaffe, Stefano A. Pileri, Harald Stein, et al., editors. Vol. 2. Lyon: International Agency for Research on Cancer (IARC); 2017."},{"issue":"2","key":"2939_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156.","journal-title":"Cancer Discov."},{"issue":"51","key":"2939_CR8","doi-asserted-by":"publisher","first-page":"e9452","DOI":"10.1097\/MD.0000000000009452","volume":"96","author":"S Grushchak","year":"2017","unstructured":"Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, et al. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report. Medicine (Baltimore). 2017;96(51):e9452.","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"2939_CR9","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","volume":"104","author":"G Reda","year":"2019","unstructured":"Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, D\u2019Incalci M, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement. Haematologica. 2019;104(5):e222.","journal-title":"Haematologica."},{"issue":"15","key":"2939_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMc1808354","volume":"379","author":"ME Agha","year":"2018","unstructured":"Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2018;379(15):1479\u201381. https:\/\/doi.org\/10.1056\/NEJMc1808354.","journal-title":"N Engl J Med."},{"key":"2939_CR11","doi-asserted-by":"publisher","first-page":"106199","DOI":"10.1016\/j.leukres.2019.106199","volume":"85","author":"G Beziat","year":"2019","unstructured":"Beziat G, Ysebaert L, Gaudin C, Steinmeyer Z, Balardy L. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: a case-report and review of literature. Leukemia Research. 2019;85:106199.","journal-title":"Leukemia Research."},{"key":"2939_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00277-020-03939-1","volume":"99","author":"M Piccini","year":"2020","unstructured":"Piccini M, Loscocco GG, Gianfaldoni G, Grieco P, Palmieri G, Pilerci S, et al. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm. Ann Hematol. 2020;99:907\u20139.","journal-title":"Ann Hematol."},{"key":"2939_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220951850","author":"Y Samhouri","year":"2020","unstructured":"Samhouri Y, Ursu S, Dutton N, Tanvi V, Fazal S. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. J Oncol Pharm Pract. 2020. https:\/\/doi.org\/10.1177\/1078155220951850.","journal-title":"J Oncol Pharm Pract."},{"issue":"3","key":"2939_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385\u201392.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2939_CR15","first-page":"1","volume":"130","author":"N Pemmaraju","year":"2017","unstructured":"Pemmaraju N, Sweet KL, Lane AA, Stein AS, Vasu S, Blum W, et al. Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 2017;130(Suppl 1):1.","journal-title":"Blood."},{"issue":"17","key":"2939_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628\u201337.","journal-title":"N Engl J Med"},{"issue":"8","key":"2939_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848\u201358.","journal-title":"Blood Adv"},{"issue":"8","key":"2939_CR18","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","volume":"25","author":"S Arcangeli","year":"2017","unstructured":"Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25(8):1933\u201345.","journal-title":"Mol Ther"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02939-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T20:03:14Z","timestamp":1624651394000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02939-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"22 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This report has been approved by the Ethics Committee of Hospital de la Santa Creu i Sant Pau and all of the research has been performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"326"}}